MARKET WIRE NEWS

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

MWN-AI** Summary

Cosmos Health Inc. (NASDAQ:COSM) has announced the launch of its food supplements brand, Sky Premium Life, in Albania, partnering with Pharma Cell, a prominent distributor in the region. This collaboration has begun with an initial annual order valued at $300,000, indicating a strong start for the brand's entry into the Albanian market. Pharma Cell, founded in 2021 by CEO Elvis Punmira, quickly established itself in the pharmaceutical sector, leveraging a family legacy that dates back to the 1990s. The company specializes in high-quality food supplements and has rapidly developed a network catering to pharmacies and healthcare professionals across Albania.

Cosmos Health's CEO, Greg Siokas, expressed optimism about this partnership, highlighting the ongoing growth of Sky Premium Life internationally and the potential for future expansions with Pharma Cell. Cosmos Health, incorporated in 2009, operates as a diversified, vertically integrated global healthcare group, with an extensive portfolio of proprietary pharmaceutical and nutraceutical brands, including Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®. Its manufacturing subsidiary, Cana Laboratories S.A., adheres to European Good Manufacturing Practices and produces a range of healthcare products within the EU.

Beyond distribution, Cosmos Health is engaged in substantial R&D initiatives, targeting major health issues like obesity, diabetes, and cancer, while also exploring telehealth avenues through its acquisition of ZipDoctor, Inc. The company aims to broaden its operations across Europe, Asia, and North America and currently maintains offices and distribution centers in Greece and the UK. This expansion reflects Cosmos Health's commitment to innovation in healthcare and its strategic positioning for growth within the industry.

MWN-AI** Analysis

Cosmos Health Inc. (NASDAQ: COSM) has made a significant strategic move by launching its Sky Premium Life brand in Albania through a partnership with Pharma Cell. The initial $300,000 order marks an exciting entry into a market with substantial growth potential, driven by rising health awareness and demand for high-quality supplements in the region.

Investors should consider the implications of this collaboration in light of Cosmos Health’s broader strategy. The partnership not only demonstrates management’s commitment to expanding its geographical footprint but also positions the company to penetrate the Albanian market with a trusted local distributor. Pharma Cell's rapid growth and established network of pharmacies and healthcare professionals will likely facilitate the brand's acceptance and customer base expansion.

Cosmos Health’s strong brand portfolio, including proprietary products like Mediterranation and C-Sept, coupled with robust manufacturing capabilities certified by the European Medicines Agency (EMA), enhances its market competitiveness. Furthermore, the company’s focus on R&D and innovative partnerships targeting significant health issues such as obesity and diabetes can lead to future product innovations, propelling long-term growth prospects.

Investors should assess the potential risks highlighted in Cosmos Health’s customary forward-looking statements, including market volatility exacerbated by geopolitical events such as the war in Ukraine, which could impact operations. However, the ongoing diversification strategy, including ventures into telehealth via ZipDoctor, suggests a robust framework for mitigating such risks while positioning the company for dynamic market shifts.

Overall, investors could view Cosmos Health’s launch in Albania as a promising step towards greater market penetration and revenue diversification. Keeping an eye on forthcoming financial results and market expansion strategies will be crucial for informed investment decisions.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the launch of its Sky Premium Life food supplements brand in Albania, in partnership with Pharma Cell , a leading consumer health and medical supplement company that will serve as the distributor in the country.

Cosmos Health has secured an initial annual order worth $300,000 and anticipates further scaling its collaboration with Pharma Cell over time.

Pharma Cell, based in Tirana, is a fast-growing pharmaceutical company specializing in the import and export of high-quality food supplements. Founded in 2021 by CEO Elvis Punmira, an economist with over 18 years of industry experience, the company builds on a family legacy in the pharma sector dating back to the 1990s. With distribution rights for several international brands, Pharma Cell has rapidly expanded its presence across the country, serving a growing network of pharmacies and healthcare professionals.

Greg Siokas, CEO of Cosmos Health, stated: "Sky Premium Life continues to see strong international growth, and it’s a great pleasure to welcome our new collaboration with Pharma Cell. We look forward to working together to deliver outstanding results and establish the brand’s presence in Albania.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653



Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.

FAQ**

How does Cosmos Holdings Inc. COSM plan to leverage its partnership with Pharma Cell to enhance the Sky Premium Life brand's market presence in Albania and what are the expected revenue projections from this collaboration?
Cosmos Holdings Inc. (COSM) plans to leverage its partnership with Pharma Cell by enhancing the distribution and visibility of the Sky Premium Life brand in Albania, aiming for significant revenue growth through expanded market access and strong local presence, though specific projections remain unannounced.
Given the recent launch of Sky Premium Life in Albania, what strategies will Cosmos Holdings Inc. COSM implement to ensure sustained growth in the highly competitive healthcare supplement market?
Cosmos Holdings Inc. will focus on strategic partnerships, targeted marketing campaigns, product differentiation, quality assurance, and leveraging e-commerce platforms to capture market share and foster sustained growth in Albania's competitive healthcare supplement sector.
What role will the telehealth platform acquired by Cosmos Holdings Inc. COSM play in supporting the distribution and marketing efforts for Sky Premium Life's product line in Albania?
The telehealth platform acquired by Cosmos Holdings Inc. will enhance the distribution and marketing efforts for Sky Premium Life's product line in Albania by facilitating direct consumer engagement, improving service accessibility, and enabling streamlined product offerings.
How does Cosmos Holdings Inc. COSM intend to manage potential risks related to the volatile geopolitical environment and its impact on operations, particularly in relation to its partnership in Albania?
Cosmos Holdings Inc. plans to manage geopolitical risks through strategic partnerships, comprehensive risk assessments, and diversifying operations to mitigate potential impacts on its Albanian venture while maintaining operational continuity and stakeholder communication.

**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).

Cosmos Health Inc.

NASDAQ: COSM

COSM Trading

2.67% G/L:

$0.2572 Last:

2,524,082 Volume:

$0.2525 Open:

COSM Ad 300

COSM Latest News

COSM Stock Data

$15,496,877
28,036,959
21.86%
6
N/A
Medical Distributors
Healthcare
US
Thessaloniki

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App